title: Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: a single center experience.
abstract: BACKGROUND
  The clinical course of the neoplasm may vary due to both patient and tumor cell characteristics.
  
  
  OBJECTIVE
  The aim of this study was to research the influence of certain clinical and pathological features on the prognosis of early stage breast cancer.
  
  
  METHODS
  This study included 117 women that were treated and followed-up in between the years 2001-2011. The demographic, clinical and histopathological features of the cases were reviewed retrospectively.
  
  
  METHODS
  In categorical comparisons between groups, cross-tab statistics were provided and significance levels were estimated using chi-square test. Cox regression analysis, Pearson and Spearman correlation tests, and the Kaplan-Meier test were also used.
  
  
  RESULTS
  With an average of 35-months follow-up, the mean disease-free survival of patients was 91 months and the mean overall survival time was 132 months. In the whole study group, the disease-free survival rates were 88, 84, 83 and 52%, while the overall survival rates 95, 94, 83, and 83% within the first, third, fifth and tenth years, respectively. The disease- free and overall survival rates were decreased with increasing tumor grades, though this was not statistically significant. The presence of lymphovascular invasion, positive staining with Ki67 and postmenopausal status were associated with shorter disease-free and overall survival times. In multivariate analysis, only age and Her2/ neu receptor status influenced the prognosis significantly.
  
  
  CONCLUSIONS
  In parallel to clinical, histopathological, and immunohistochemical prognostic features in breast cancer, in this study positive Her2/neu receptor status, a previously accepted poor prognostic factor, was found to have positive influence after trastuzumab treatment.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey E-mail : mugla.medicaloncology@gmail.com or ozgur.tanriverdi@yahoo.com.
authors.forename: Ozgur
authors.initials: O
authors.lastname: Tanriverdi
authors.forename: Nezih
authors.initials: N
authors.lastname: Meydan
authors.forename: Sabri
authors.initials: S
authors.lastname: Barutca
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases